Journal of Hepatology
Volume 53, Issue 2 , Pages 261-266 , August 2010

Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy

  • Won Young Tak

      Affiliations

    • Department of Internal Medicine, Liver Research Institute, Graduate School of Medicine, Kyungpook National University, Daegu, Republic of Korea
    • Corresponding Author InformationCorresponding author. Address: Department of Internal Medicine, Kyungpook National University Hospital, 200 Dongduk-Ro, Jung-Gu, Daegu 700-721, Republic of Korea. Tel.: +82 53 420 5519; fax: +82 53 426 8773.
    • Drs. Tak and Park share the first authorship of this article.
    • ,
  • Soo Young Park

      Affiliations

    • Department of Internal Medicine, Liver Research Institute, Graduate School of Medicine, Kyungpook National University, Daegu, Republic of Korea
    • Drs. Tak and Park share the first authorship of this article.
    • ,
  • Chang Min Cho

      Affiliations

    • Department of Internal Medicine, Liver Research Institute, Graduate School of Medicine, Kyungpook National University, Daegu, Republic of Korea
    • ,
  • Min Kyu Jung

      Affiliations

    • Department of Internal Medicine, Liver Research Institute, Graduate School of Medicine, Kyungpook National University, Daegu, Republic of Korea
    • ,
  • Seong Woo Jeon

      Affiliations

    • Department of Internal Medicine, Liver Research Institute, Graduate School of Medicine, Kyungpook National University, Daegu, Republic of Korea
    • ,
  • Young Oh Kweon

      Affiliations

    • Department of Internal Medicine, Liver Research Institute, Graduate School of Medicine, Kyungpook National University, Daegu, Republic of Korea
    • ,
  • Ji Young Park

      Affiliations

    • Department of Pathology, Graduate School of Medicine, Kyungpook National University, Daegu, Republic of Korea
    • ,
  • Yoon Kyung Sohn

      Affiliations

    • Department of Pathology, Graduate School of Medicine, Kyungpook National University, Daegu, Republic of Korea

Received 21 October 2009 ,Revised 4 March 2010 ,Accepted 9 March 2010.

References 

  1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107
  2. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2008;28:167–177
  3. Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med. 2009;150:111–124
  4. Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (−)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother. 2001;45:2495–2501
  5. Chu CK, Ma T, Shanmuganathan K, Wang C, Xiang Y, Pai SB, et al. Use of 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein–Barr virus. Antimicrob Agents Chemother. 1995;39:979–981
  6. Yao GQ, Liu SH, Chou E, Kukhanova M, Chu CK, Cheng YC. Inhibition of Epstein–Barr virus replication by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Biochem Pharmacol. 1996;51:941–947
  7. Balakrishna Pai S, Liu SH, Zhu YL, Chu CK, Cheng YC. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Antimicrob Agents Chemother. 1996;40:380–386
  8. Ma T, Pai SB, Zhu YL, Lin JS, Shanmuganathan K, Du J, et al. Structure–activity relationships of 1-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents. J Med Chem. 1996;39:2835–2843
  9. Chu CK, Boudinot FD, Peek SF, Hong JH, Choi Y, Korba BE, et al. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir Ther. 1998;3(Suppl. 3):113–121
  10. Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2007;45:1172–1178
  11. Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology. 2007;46:1041–1048
  12. Tak WY, Park SY, Jung MK, Jeon SW, Cho CM, Kweon YO, et al. Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients. Hepatol Res. 2009;39:944–947
  13. Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology. 2009;49:2080–2086
  14. Kim BK, Oh J, Kwon SY, Choe WH, Ko SY, Rhee KH, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol. 2009;51:829–834
  15. European Association for Study of Liver Disease. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–242
  16. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662
  17. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19:1409–1417
  18. Vincent KA, Carr AJ, Walburn J, Scott DL, Rose MR. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology. 2007;68:1051–1057
  19. Gregson JM, Leathley MJ, Moore AP, Smith TL, Sharma AK, Watkins CL. Reliability of measurements of muscle tone and muscle power in stroke patients. Age Ageing. 2000;29:223–228
  20. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995;333:1099–1105
  21. Lee HS, Chung YH, Lee K, Byun KS, Paik SW, Han JY, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2006;43:982–988
  22. Dagan T, Sable C, Bray J, Gerschenson M. Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence?. Mitochondrion. 2002;1:397–412
  23. Hu R, Li L, Degreve B, Dutschman GE, Lam W, Cheng YC. Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2′-deoxy-2′-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2′,3′-didehydro-2′,3′-dideoxythymidine in cells. Antimicrob Agents Chemother. 2005;49:2044–2049
  24. Krishnan P, Fu Q, Lam W, Liou JY, Dutschman G, Cheng YC. Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J Biol Chem. 2002;277:5453–5459
  25. Liu SH, Grove KL, Cheng YC. Unique metabolism of a novel antiviral L-nucleoside analog, 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob Agents Chemother. 1998;42:833–839
  26. Tehrani OS, Douglas KA, Lawhorn-Crews JM, Shields AF. Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2. Eur J Nucl Med Mol Imaging. 2008;35:1480–1488
  27. Lim SG, Leung N, Hann HW, Lau GK, Trepo C, Mommeja-Marin H, et al. Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2008;27:1282–1292
  28. Marcellin P, Mommeja-Marin H, Sacks SL, Lau GK, Sereni D, Bronowicki JP, et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology. 2004;40:140–148
  29. Ko SY, Kwon SY, Choe WH, Kim BK, Kim KH, Lee CH. Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study. Antivir Ther. 2009;14:585–590
  30. Zhang XS, Jin R, Zhang SB, Tao ML. Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol. 2008;14:3549–3553

PII: S0168-8278(10)00269-2

doi: 10.1016/j.jhep.2010.03.006

Journal of Hepatology
Volume 53, Issue 2 , Pages 261-266 , August 2010

Article Tools

* Image Usage & Resolution